Shots:

• The IDMC has recommended stopping the enrollment in the P-III COMET-ICE trial due to evidence of profound efficacy. The study involves assessing VIR-7831 (GSK4182136) vs PBO in 583 patients for the early treatment of COVID-19 in adults at high risk of hospitalization
• The results demonstrated an 85% reduction in hospitalization or death and were well tolerated. The ongoing trial will continue to be followed for 24wks.
• Vir and GSK plan to submit a EUA to the FDA and for authorization in other countries. Additionally- the company also reported the results of new in vitro studies that indicate VIR-7831 maintains activity against major circulating COVID-19 variants

 ­ Ref: GlobeNewswire | Image: GSK